Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | MEN1 | O00255 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22425033 | 0.91 | MAPT (0.74) | MAPTMEN1KMT2ARXFP1POLB | |
| SCHEMBL22425115 | 0.87 | MAPT (0.73) | MAPTMEN1KMT2APOLBGAA | |
| SCHEMBL22425070 | 0.86 | MAPT (0.67) | MAPTMEN1KMT2ARXFP1TP53 | |
| SCHEMBL24430209 | 0.85 | MAPT (1.00) | MAPTMEN1KMT2APOLBGAA | |
| SCHEMBL22425306 | 0.85 | MAPT (0.73) | MAPTMEN1KMT2ARXFP1POLB | |
| SCHEMBL24430194 | 0.83 | MAPT (0.70) | MAPTMEN1KMT2AMAPK1TP53 | |
| SCHEMBL24430181 | 0.82 | MAPT (0.69) | MAPTMEN1KMT2ARXFP1POLB | |
| SCHEMBL19427443 | 0.82 | MEN1 (0.75) | MAPTMEN1KMT2APOLBGAA | |
| SCHEMBL22425132 | 0.82 | MEN1 (0.58) | MAPTMEN1KMT2APOLBGAA | |
| SCHEMBL19427492 | 0.82 | MEN1 (0.84) | MAPTMEN1KMT2APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-16 | — | — | US | disclosed |
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2020186202-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | GRB2, KRAS, HRAS | MAPT 3372/4885MEN1 2474/4885KMT2A 2941/4885 |
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | GRB2, RAD51, MRE11 | MAPT 4193/4885MEN1 3237/4885KMT2A 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.